Shock Daniel, Roche Steven, Olson Merle
ACER Consulting, Guelph, ON N1G 5L3, Canada.
Alberta Veterinary Laboratories, Calgary, AB T2E 6J7, Canada.
Vet Sci. 2019 Sep 5;6(3):73. doi: 10.3390/vetsci6030073.
The dairy industry needs evidence-based solutions to mitigate painful procedures and conditions in dairy cattle. The objective of this study was to compare the pharmacokinetic properties of orally versus subcutaneously administered meloxicam in early-lactation dairy cattle. The study was conducted at a commercial dairy herd in southwestern Ontario, Canada. Twelve postpartum cows were enrolled in the study, receiving either subcutaneous meloxicam (MET) at 0.5 mg/kg body weight (n = 6) or oral meloxicam (MOS) at a higher dose of 1.0 mg/kg body weight (n = 6) immediately following parturition. The predicted half-life (12.5 ± 2.0 vs. 28.5 ± 2.0 h), C (1.59 ± 0.15 vs. 1.95 ± 0.16 μg/mL), T (5.33 vs. 11.7 h), and AUC (39.6 ± 7.4 vs. 115.6 ± 19 h * µg/mL) differed significantly between MET and MOS cows, respectively. After controlling for the treatment group, first lactation cows had a significantly higher half-life (4.1 ± 2.1 h), C (0.56 ± 0.2 µg/mL), and AUC (21.6 ± h * µg/mL) relative to second lactation or greater cows, respectively. Administration of meloxicam through the subcutaneous or oral route results in appreciable, dose-dependent systemic levels.
乳制品行业需要基于证据的解决方案来减轻奶牛的痛苦程序和状况。本研究的目的是比较在初产奶牛中口服与皮下注射美洛昔康的药代动力学特性。该研究在加拿大安大略省西南部的一个商业奶牛场进行。12头产后奶牛参与了该研究，在分娩后立即接受皮下注射美洛昔康（MET），剂量为0.5 mg/kg体重（n = 6）或口服较高剂量1.0 mg/kg体重的美洛昔康（MOS）（n = 6）。MET组和MOS组奶牛的预测半衰期（分别为12.5 ± 2.0与28.5 ± 2.0小时）、Cmax（分别为1.59 ± 0.15与1.95 ± 0.16 μg/mL）、Tmax（分别为5.33与11.7小时）和AUC（分别为39.6 ± 7.4与115.6 ± 19小时μg/mL）存在显著差异。在控制治疗组后，相对于二胎或更高胎次的奶牛，头胎奶牛的半衰期（4.1 ± 2.1小时）、Cmax（0.56 ± 0.2 μg/mL）和AUC（21.6 ±小时μg/mL）显著更高。通过皮下或口服途径给药美洛昔康会导致明显的、剂量依赖性的全身血药浓度。
